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The transmembrane protein Ci-VSP from the ascidian Ciona intestinalis was described as
ﬁrst member of a fascinating family of enzymes, the voltage sensitive phosphatases
(VSPs). Ci-VSP and its voltage-activated homologs from other species are stimulated
by positive membrane potentials and dephosphorylate the head groups of negatively
charged phosphoinositide phosphates (PIPs). In doing so, VSPs act as control centers at
the cytosolic membrane surface, because they intervene in signaling cascades that are
mediated by PIP lipids. The characteristic motif CX5RT/S in the active site classiﬁes VSPs
as members of the huge family of cysteine-based protein tyrosine phosphatases (PTPs).
Although PTPs have already beenwell-characterized regarding both, structure and function,
their relationship to VSPs has drawn only limited attention so far. Therefore, the intention
of this review is to give a short overview about the extensive knowledge about PTPs in
relation to the facts known about VSPs. Here, we concentrate on the structural features
of the catalytic domain which are similar between both classes of phosphatases and
their consequences for the enzymatic function. By discussing results obtained from
crystal structures, molecular dynamics simulations, and mutagenesis studies, a possible
mechanism for the catalytic cycle of VSPs is presented based on that one proposed for
PTPs. In this way, we want to link the knowledge about the catalytic activity of VSPs and
PTPs.
Keywords: cysteine-based phosphatase, dual-specific phosphatase, acid phosphatase, low molecular weight
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INTRODUCTION
Phosphorylation and dephosphorylation of cellular substrates,
such as proteins, lipids, carbohydrates or nucleic acids, are crucial
for the precise spatiotemporal transduction of signals across the
cellular space. While phosphorylation of substrates is mediated by
kinases, phosphatases attack their substrates by hydrolyzing cova-
lently attached phosphate groups. In this context, protein tyrosine
phosphatases (PTPs1) come into play with their dephosphoryla-
tion activity toward a diverse pool of cellular substrates. Members
of this huge protein family are involved in multiple processes like
endo- and exocytosis, cell differentiation, cell proliferation and
migration – to list only a few examples. Because of this broad
spectrum in activity, it is not surprising that malfunctions of
PTPs are associated with various diseases, for example neuro-
logical disorders, diabetes, or cancer (Cohen, 2001; Tautz et al.,
2013).
Most PTPs are very similar in the structure of their cat-
alytic domain. Consequently, a medicinal treatment that should
be speciﬁc just for one phosphatase bears always the risk of
unwanted side effects since the drug may act on more than one of
these enzymes. Therefore, the development of new medications
1A list of all abbreviations used in this text is given in Table S1.
requires a detailed knowledge about the individuality of PTPs,
and here – in particular – about the molecular details of sub-
strate recognition, activation and catalysis, about the mechanisms
that regulate their activity, and about their functional role in spe-
ciﬁc signaling cascades (Zhang, 2001; Scott et al., 2010; He et al.,
2014).
Voltage-sensitive phosphatases (VSPs) belong to the PTP family
due to their homology in amino acid sequence of the active site and
similarities in their structure of the catalytic domain. In VSPs, the
phosphatase activity is directly coupled to the membrane poten-
tial. This voltage-switchable activity qualiﬁes VSPs as ideal model
systems to study enzymatic mechanisms of PTPs under deﬁned
experimental conditions.
Since the ﬁrst identiﬁcation of a PTP in Tonks et al. (1988a,b),
a lot of studies have been performed leading to a huge amount
of detailed information about these enzymes. However, although
VSPs are members of the PTP family, their relationship has only
been marginally discussed so far. In this review, we will address
structural and mechanistic similarities of VSPs and PTPs. By link-
ing the knowledge about these phosphatases,wewant to answer the
question if the results achieved for VSPs can be integrated into the
set of principles which have already been described in more detail
for PTPs.
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GENERAL CLASSIFICATION OF PTPs
The classiﬁcation of PTPs is primarily based on their catalytic
mechanism. Two different kinds of PTP subfamilies exist, the
so called cysteine-based and the aspartate-based PTPs. Here,
the name implies the key residue that mediates the dephos-
phorylation step in the reaction cycle of the respective class of
enzymes. Although using a similar pool of substrates, cysteine-
and aspartate-based PTPs are completely different in structure and
the enzymatic reaction mechanism. Because this review will focus
on cysteine-based PTPs, the reader interested in aspartate-based
PTPs is referred to the excellent reviews by Moorhead et al. (2007,
2009).
The hallmark of all cysteine-based PTPs is the CX5RS/T
sequence motif in their active site. Besides this so-called PTP
recognition loop or P-loop, cysteine-based PTPs can be further
categorized into three subclasses, I to III, based on their similar-
ities in amino acid sequence, structure, and substrate speciﬁcity.
The excellent overview of Alonso et al. (2004) is recommended
here for a detailed classiﬁcation of cysteine-based PTPs. However,
for the sake of completeness, a short summary about the three
PTP subclasses is also given here.
Class I PTPs – the classical and dual-speciﬁc PTPs
Class I PTPs form the largest subfamily of cysteine-based PTPs
known so far. Their expressionhas beendetected in all formsof life,
from bacteria, yeast, plants to mammals (Pawson and Scott, 2005;
Moorhead et al., 2009). This class of phosphatases comprises two
subfamilies, the“classical”and the“dual-speciﬁc”PTPs (Figure 1).
Classical PTPs show strict substrate speciﬁcity for phos-
photyrosine (pTyr) residues. They are further categorized into
receptor-like PTPs (rPTPs), which are anchored in the membrane,
and non-transmembrane PTPs, which are located intracellularly.
A famous example for a receptor-like classical PTP is CD45,
a transmembrane PTP that is expressed on the surface of leuco-
cytes. Particularly in T lymphocytes, CD45 plays an essential role
in the signal transduction that is initiated through the antigen-
stimulation of the T cell receptor at the membrane surface (Altin
and Sloan, 1997; Hermiston et al., 2003).
One prominent example for a non-transmembrane classi-
cal PTP is PTP1B, the founding member of the cysteine-based
PTP superfamily (Tonks et al., 1988a,b). This soluble enzyme has
attracted special attention in recent years, because it is well-known
to act as negative regulator in the insulin signaling pathway. There-
fore, it is a core subject of current pharmaceutical research as
potential target for the treatment of type 2 diabetes and obesity
(Goldstein, 2001; Zhang and Zhang, 2007; Combs, 2010). Besides
that, PTP1B has also been discussed as putative drug target for
breast cancer therapies (Yip et al., 2010; Feldhammer et al., 2013).
However, interpretation of experimental results in this ﬁeld needs
careful consideration since there are hints that PTP1B might act in
both directions, tumor suppression and promotion (Lessard et al.,
2010).
In contrast to classical PTPs, phosphatases with the CX5RT/S
motif in their active site and with activity toward more than
pTyr substrates are categorized as dual-speciﬁc PTPs (DUSPs).
DUSPs are the most diverse subclass among cysteine-based PTPs
in terms of their substrate speciﬁcity. As described in more detail
in the reviews of Alonso et al. (2004) and Tautz et al. (2013),
they comprise phosphatases with activity toward protein- and/or
non-protein substrates (Figure 1). Examples for protein-speciﬁc
DUSPs are the phosphothreonine (pThr)-/pTyr-speciﬁc MAPK
phosphatases (MKPs), the pSer-speciﬁc slingshots (SSHs), and
the pSer-/pThr-speciﬁc Cdc14s.
Several DUSPs dephosphorylate more than protein-derived
substrates. Examples for these phosphatases are the mRNA-
speciﬁc phosphatase DUSP11 (also referred to as PIR1;
Yuan et al., 1998), the phosphoinositol-speciﬁc PTENs (phos-
phatase and tensin homologs), MTMs (myotubularins) and
INPP4s (inositol-4-phosphatases; Liu and Bankaitis, 2010; Kim
et al., 2013), and the carbohydrate-speciﬁc phosphatase laforin
(Ganesh et al., 2000).
For the following discussion, we selected only a few examples
to illustrate general features of DUSPs regarding their structural,
catalytic, and functional properties. We are aware that this can just
give a rough insight into this ﬁeld, because of the huge amount of
information being available about this subclass of enzymes.
The ﬁrst member of DUSPs described was VH1 from the vac-
cinia virus (Guan et al., 1991). This enzyme dephosphorylates
pSer, pThr, and pTyr residues in vitro and in vivo (Guan andDixon,
1991; Derrien et al., 1999). Included in the encapsidated ﬂuid of
vaccinia virions,VH1 is released into the intracellular space during
the infection of a cell. Here, it dephosphorylates Stat1, an effec-
tor molecule of the host cell, which otherwise would initiate the
antiviral immune response (Najarro and Traktman, 2001; Mann
et al., 2008). In addition to that, VH1 activates own viral proteins
by dephosphorylating them during the infection of a cell, i. a.
those ones that mediate the viral morphogenesis (Liu et al., 1995;
Derrien et al., 1999). In this way, VH1 is crucial for maintaining
the viability of the virus.
Theﬁrst homolog toVH1 found inhumanswasVHR(Ishibashi
et al., 1992). This phosphatase hydrolyzes pTyr-/pThr-residues
derived from MAP-kinases, such as Erk and Jnk and, thus,
downregulates signaling cascades that are associated with cell pro-
liferation and differentiation (Ishibashi et al., 1992; Denu et al.,
1995b; Todd et al., 1999; Alonso et al., 2001).
Another human VH1-related phosphatase, DUSP11, specif-
ically dephosphorylates mRNA and shows less activity
toward phosphoproteins. Because DUSP11 interacts with the
RNA/ribonucleoprotein-complex, it is proposed to be involved
in the cellular mRNA metabolism (Yuan et al., 1998; Deshpande
et al., 1999; Sankhala et al., 2014).
One of the most prominent members of non-protein-speciﬁc
DUSPs is the tumor suppressor phosphatase PTEN. This enzyme
was initially identiﬁed by screening diverse tumor-derived tis-
sues as one of the most frequently mutated proteins (Li et al.,
1997). Based on the P-loop motif in its active site, the cytoso-
lic phosphatase was primarily believed to be a cysteine-based
PTP speciﬁc for phosphorylated protein substrates. Shortly after
its discovery, it has been demonstrated that PTEN is indeed a
dual-speciﬁc class I PTP with dephosphorylation activity toward
pTyr, pSer, and pThr residues in vitro (Furnari et al., 1997; Li
and Sun, 1997; Myers et al., 1997). However, follow-up stud-
ies demonstrated that PTEN’s main substrate preference in vivo
is toward the 3′-position of the phosphoinositide (PI) species
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FIGURE 1 | Overview about the classification scheme of cysteine-based
PTPs. Members of individual subfamilies, which were exemplarily chosen and
discussed in the main text, are listed in their respective PTP subclass. The
preferred substrates of these phosphatases are given. Substrates that can be
dephosphorylated, but with less preference are mentioned in parentheses.
Abbreviations used here are explained in Table S1.
PI(3,4,5)P3 at the inner cell membrane surface (Myers et al.,
1997, 1998). Thus, PTEN counteracts the PI3K-signaling cascade,
which otherwise leads to unrestricted cell growth with signiﬁ-
cantly increased susceptibility for tumor genesis (Knobbe et al.,
2002; Leslie and Downes, 2002; Zhang and Yu, 2010; Miller et al.,
2011).
One last example for DUSPs should be mentioned here:
laforin. This human enzyme is the only phosphatase known
so far that dephosphorylates complex carbohydrates (Worby
et al., 2006; Tagliabracci et al., 2007). Laforin is further capa-
ble to dephosphorylate pTyr, pSer, and pThr residues in vitro
(Ganesh et al., 2000) and pSer in vivo (Lohi et al., 2005). Mis-
sense mutations in the respective gene, EMP2A, which disrupt
the activity of the phosphatase, are associated with a fatal
progressive autosomal recessive form of myoclonic epilepsy, the
Lafora disease (Tagliabracci et al., 2007). The mechanism by which
laforin prevents the disease is only poorly understood. First
results indicate that the phosphatase intervenes in the glycogen
metabolism and prevents the formation of polyglucosan inclu-
sion bodies in the cytosol of almost all cell types. These so-called
“Lafora bodies” are a typical symptom of the disease (Wang et al.,
2002; Fernández-Sánchez et al., 2003; Tagliabracci et al., 2007;
Roach et al., 2012).
All these facts illustrate the broad substrate spectrum
of DUSPs and their crucial relevance in human physi-
ology. For further information about these phosphatases,
the reader is referred to the detailed reviews listed here
(Tronchère et al., 2003; Pulido and van Huijsduijnen, 2008;
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Liu and Bankaitis, 2010; Pulido et al., 2013; Tautz et al., 2013;
He et al., 2014).
It should be noted, that the similarity of classical, dual-speciﬁc,
and non-protein-/dual-speciﬁc phosphatases is largely restricted
to the P-loop in the active site and the conservation of the folding
pattern of the catalytic domain. The domains and regions that
ﬂank the phosphatase domain are diverse among class I PTPs, and
specify their differences in cellular localization, activation, and
regulation.
Class II PTPs – the low molecular weight PTPs
Class II PTPs are the so-called “low molecular weight” PTPs
(LMW-PTPs). With ∼15-18 kDa, these phosphatases are smaller
than class I PTPs that have a molecular weight of at least ∼30–
50 kDa. Due to their catalytic activity at pH values≤6, LMW-PTPs
have also been classiﬁed as acid phosphatases (ACPs; Hopkinson
et al., 1963; Lawrence and Van Etten, 1981; Lucentini et al., 2003).
LMW-PTPs are soluble phosphatases with substrate speciﬁcity for
pTyr substrates (Zhang and Van Etten, 1991; Stefani et al., 1993),
but not for pSer or pThr residues (Ramponi et al., 1989; Wo et al.,
1992).
Originally isolated from human red cells (Hopkinson et al.,
1963), LMW-PTPs have been found in numerous prokaryotes
and eukaryotes (Ramponi and Stefani, 1997a; Raugei et al., 2002).
In mammals, they are ubiquitously expressed with no partic-
ular tissue-speciﬁc distribution (de Araujo et al., 1976; Zhang
and Van Etten, 1990; Ramponi and Stefani, 1997b). Up to
now, four human isoforms have been identiﬁed. All of them
are splice variants of the transcription product of the ACP1
gene (Raugei et al., 2002). Two catalytically active isoforms, IF1
and IF2 (also named as HCPTPA and HCPTPB), differ only
in a short sequence that spans one of the loop regions sur-
rounding the active site. This variation in structure causes
differences in both, substrate speciﬁcity and binding afﬁnities
against modulating ligands (Wo et al., 1992; Cirri et al., 1996;
Ramponi and Stefani, 1997a). Apart from that, two other human
splice variants of the ACP1 transcription product have been
described, SV3 and LMW-PTP-C. Both isoforms seem to be
catalytically inactive, but might regulate the active isoenzymes
through the competition for substrate binding (Modesti et al.,
1998; Tailor et al., 1999).
In mammals, catalytically active LMW-PTPs downregulate
the activity of several tyrosine kinase receptors, for exam-
ple the insulin receptor (Chiarugi et al., 1997), the vascular
endothelial (Huang et al., 1999), the epidermal (Ramponi et al.,
1989), and the ﬁbroblast growth factor receptor (Park et al.,
2002). Moreover, LMW-PTPs also regulate the cellular reac-
tion to platelet-derived growth factor stimulation (Chiarugi
et al., 2000). Because LMW-PTPs are involved in a variety
of signaling cascades, the reduction or loss of their activ-
ity leads to different pathologic manifestations (Bottini et al.,
2002), including allergy and asthma (Bottini et al., 2007),
autoimmune diseases (Bottini et al., 2000), and neurodegener-
ative disorders like the Alzheimer’s disease (Shimohama et al.,
1993, 1995). In particular, since LMW-PTPs play a crucial
role in mitogenic signaling pathways, their malfunction entails
high oncogenic potential (Malentacchi et al., 2005; Alho et al.,
2008). Therefore, LMW-PTPs form another class of target
molecules for therapeutics against serious diseases, including
cancer (Homan et al., 2010; Mascarello et al., 2010; Seiler et al.,
2013).
Class III PTPs – the Cdc25 phosphatases
Class III PTPs belong to the family of cell division control proteins
(Cdc). According to this nomenclature, class III PTPs are named as
Cdc25. Initially characterized in yeast (Russell and Nurse, 1984),
these phosphatases are expressed in all eukaryotes (Boutros et al.,
2007; Rudolph, 2007) except plants (Boudolf et al., 2006). Up to
now, three isoforms have been identiﬁed in humans: Cdc25A, B
and C (Galaktionov and Beach, 1991).
Cdc25 isoforms speciﬁcally dephosphorylate cyclin-dependent
kinases (Cdks) at their inhibitory, dually phosphorylated N-
terminal Thr-Tyr motif (Gautier et al., 1991; Krek and Nigg,
1991; Honda et al., 1993). In turn, these phosphatases show dual-
speciﬁc substrate speciﬁcity. Cdks require for their activation the
dephosphorylation by Cdc25 and, additionally, a phosphoryla-
tion mediated by Cdk-activating kinases (Kaldis, 2014). Through
this enzymatic interplay, Cdks initiate the progression through the
cell cycle (Gautier et al., 1991; Honda et al., 1993; Lammer et al.,
1998). Apart from that, Cdc25s are also involved in preventing
Cdk activation upon cellular DNA damage or incomplete repli-
cation (Kristjánsdóttir and Rudolph, 2004; Karlsson-Rosenthal
and Millar, 2006). Acting as regulator of the eukaryotic cell cycle
qualiﬁes Cdc25 phosphatases as promising targets for anti-cancer
therapeutics (Kristjánsdóttir and Rudolph, 2004; Rudolph, 2007).
Because Cdc25s dephosphorylate more than pTyr substrates,
they are often called dual-speciﬁc phosphatases. This nomen-
clature might cause confusion by mixing up Cdc25s with dual-
speciﬁc phosphatases from class I PTPs. Here, it should be noted,
that despite the activity toward more than pTyr substrates, dual-
speciﬁc PTPs of class I and III are individual subfamilies with
signiﬁcant differences in protein structure.
Interestingly, Cdc25s have evolved as a unique subclass of
PTPs, but the reason for this uniqueness has been controversially
discussed. As mentioned by Alonso et al. (2004), one possible
explanation could be that ancestral Cdc25s had already acted
as rhodanese-type enzymes – a class of sulfur-transfer proteins
(Cipollone et al., 2008) – on Cdks, but were ﬁnally transformed
into cysteine-based PTPs when the Tyr/Thr phosphorylation of
Cdks appeared. This idea is supported by the fact that the overall
structure of Cdc25s is rather similar to rhodanese enzymes than
to class I and II PTPs (Fauman et al., 1998; Reynolds et al., 1999;
Bordo and Bork, 2002).
Although all three subclasses I to III of the cysteine-based PTP
family share similarities regarding their catalytic mechanism and
active site structure, all of them have evolved independently from
each other (Alonso et al., 2004; Moorhead et al., 2009). From that,
the question arises: to which subclass of PTPs does the family of
VSPs belong?
INTEGRATION OF VOLTAGE SENSITIVE PHOSPHATASES INTO THE
CLASSIFICATION SYSTEM OF PTPs
The ﬁrst mammalian variants of VSPs were described in the early
2000s with publications about transmembrane phosphatases with
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tensin homology (TPTEs2; Chen et al., 1999; Guipponi et al., 2000,
2001; Walker et al., 2001; Wu et al., 2001; Tapparel et al., 2003). In
these early studies, the research had been focused only on the bio-
chemical characterization of the enzymatic activity, because the
proteins share a high sequence homology with the tumor sup-
pressor PTEN. Finally, bioinformatic analyses suggested that the
transmembrane part of these phosphatases might act as voltage
sensor domain (Kumanovics et al., 2002). However, no functional
characterization of a voltage-dependent activity was carried out at
this point.With thedescriptionof Ci-VSP (VSP fromCiona intesti-
nalis) in Murata et al. (2005), the ﬁrst experimental evidence for
the existence of a transmembrane phosphatasewith voltage-driven
activity was published.
Ci-VSP, the most prominent example of VSPs to date, can be
easily expressed in heterologous expression systems; a fact that
facilitates the electrophysiological characterization of this protein.
As other VSPs, Ci-VSP consists of a membrane-spanning volt-
age sensor domain and a cytosolic catalytic domain. The voltage
sensor domain consists of four putatively α-helical transmem-
brane segments (Li et al., 2014). The fourth segment contains
positively charged residues arranged in a periodical order as
it can be found in voltage-gated ion channels (Villalba-Galea,
2012b). The cytosolic domain consists of two subdomains, the
phosphatase and an adjacent C2 domain (Matsuda et al., 2011;
Liu et al., 2012). The phosphatase-/C2-complex of Ci-VSP shows
∼40% amino acid homology to the tumor suppressor PTEN. Due
to this fact, the phosphatase domain of Ci-VSP is structurally
related to that one of class I PTPs (Okamura and Dixon, 2011;
Villalba-Galea, 2012a).
Generally, VSPs are capable to “translate” voltage stimuli at the
plasma membrane directly into enzymatic activity in the cytosol.
Positive membrane potentials lead to conformational changes in
the voltage sensor domain that activate the intracellular catalytic
domain. In the activated state, the enzymatic domain cleaves
phosphate groups from the inositol ringof phosphoinositidephos-
phates (PIPs). In particular, Ci-VSP speciﬁcally hydrolyzes the
5′-phosphate of thePIP-species PI(3,4,5)P3 andPI(4,5)P2 (Iwasaki
et al., 2008; Halaszovich et al., 2009). Furthermore, several results
indicated a 3′-site activity toward PI(3,4)P2 for Ci-VSP when
the phosphatase was expressed in Xenopus oocytes, but with a
decrease in efﬁciency compared to the 5′-activitiy (Sakata et al.,
2011; Sakata and Okamura, 2013). Controversially, such a 3′-
speciﬁcity could not be detected when Ci-VSP was expressed
in mammalian cells (Lacroix et al., 2011; Halaszovich et al.,
2012). This discrepancy raised the question whether the 3′-site
activity of Ci-VSP is speciﬁc for the oocyte expression system
(Halaszovich et al., 2012).
After the discovery of Ci-VSP, several homologs have been
described from other species, such as zebraﬁsh (Danio rerio,
Dr-VSP; Hossain et al., 2008), chicken (Gallus gallus, Gg-VSP;
Neuhaus andHollemann,2009; Kurokawa et al., 2012), theAfrican
clawed frog (Xenopus laevis, Xl-VSP; Ratzan et al., 2011), and
2A variant of the TPTE family has been initially named as TPIP (TPTE and
PTEN homologous inositol lipid phosphatase; Walker et al., 2001), nowadays also
called TPTE2. To introduce a more consistent nomenclature, the human isoforms
of TPTEs, TPTE2 and TPTE, have also been referred to as hVSP1 and hVSP2,
respectively (Halaszovich et al., 2012).
urodele amphibians (Mutua et al., 2014). In addition, transmem-
brane phosphatases found in mammals have been characterized in
more detail in the recent years (Halaszovich et al., 2012; Kurokawa
et al., 2012; Sutton et al., 2012). Although several studies demon-
strated the expression of VSPs in testis, intestine, stomach, kidney,
and the nervous system (Chen et al., 1999; Walker et al., 2001;
Tapparel et al., 2003; Murata et al., 2005; Neuhaus andHollemann,
2009;Ogasawara et al., 2011), thephysiological role ofVSPs in their
native organisms is still elusive.
There are several isoforms of VSPs that are catalytically inactive
toward their presumed PIP-substrates, for example TPTE/hVSP2
(Walker et al., 2001; Leslie et al., 2007). However, all active isoen-
zymes share the common property of dephosphorylation activity
at positive membrane potentials. Moreover, all homologs charac-
terized so far show substrate speciﬁcity against PIP-lipids, whereas
the preference either for the 3′- or the 5′-phosphate at the inositol
ring seems to differ amongVSPs (Walker et al., 2001; Murata et al.,
2005; Iwasaki et al., 2008; Halaszovich et al., 2009, 2012; Lacroix
et al., 2011; Kurokawa et al., 2012).
In conclusion, because of the CX5RS/T motif in the active site,
VSPs belong to the family of cysteine-based PTPs. Furthermore,
the catalytic domain of VSPs shows a three-dimensional folding
that is characteristic for class I PTPs. Together with the fact that
VSPs speciﬁcally dephosphorylate PIP-lipids, the criteria are met
to classify VSPs as dual-speciﬁc class I PTPs (Figure 1).
GENERAL FOLDING OF THE CATALYTIC DOMAIN OF PTPs
The catalytic domains of cysteine-based PTPs have various folding
properties in common. For example, all of them contain a central
core consisting of highly twisted β-sheets, which are ﬂanked by
several α-helices (Figure 2A). One of the β-sheet-α-helix-loops
contains the active site motif CX5RS/T. This P-loop is highly
conserved and shares a homolog folding pattern for all cysteine-
based PTPs (Figure 2B). Although the residues in the X5-segment
vary largely between the different PTP subclasses (Figure 3A),
the superposition of the P-loop structures evinces only minor
deviations in the Cα-trace of the protein backbones of less
than 1 Å.
For all cysteine-based PTPs, the active site is located within a
crevice with the conserved cysteine at its bottom. Together with
the P-loop arginine, the catalytically active residue forms a cradle-
like structure (Figure 2B). This conformation is important for the
correct binding of the substrate and for stabilizing the active site
structure during the whole catalytic cycle. A network of hydrogen
bridges between the phosphate group of the substrate and the
backbone atoms of the P-loop further facilitates this stabilization
(Figure 2C).
The active site pocket of class I and II PTPs is ﬂanked by two
loop regions, which are named TI- andWPD-loop for class I PTPs,
and variable (orV-) andDPYY-loop for class II PTPs (Figure 3). In
both classes, these regions contain amino acids that are crucial for
the enzymatic reaction. Although the loop regions in class I and
II PTPs differ in length and sequence (Figure 3A), their existence
indicates a common principle for cysteine-based PTPs regarding
the regulation of their activity.
In class III PTPs, none of these two loops exists (Figure 2A).
However, these phosphatases usemechanisms that compensate for
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FIGURE 2 | Structural comparison of the catalytic domains of
cysteine-based PTPs. (A) Catalytic domains of exemplary chosen
phosphatases are shown. The twisted β-sheet core is colored in blue; the
α-helices surrounding the core are shown in red. The α-helix C-terminal to the
active site loop is depicted in cyan, and the regions corresponding to the P-,
TI- andWPD-loop of class I PTPs in yellow (see text for details). In case of
Cdc25s, noTI- andWPD-loop exist. The structure of Ci-VSP was taken from
the MD simulation (Hobiger et al., 2013) which was performed on the basis of
the crystal structure by Matsuda et al. (2011; PDB accession number 3awe).
All other structures were created based on the crystal structures available in
the RCSB protein data bank. The accession numbers are: 1nwe (hu-PTP1B),
1ygu (hu-CD45. Here, the catalytically active domain D1 is shown.), 1d5r
(hu-PTEN), 1vhr (hu-VHR), 1dg9 (bt-BHPTP), and 1qb0 (hu-Cdc25B).
Abbreviations are: hu, human; bt, bos taurus; and BHPTP, bovine heart PTP.
(B)The P-loop motif and the following α-helix are structurally aligned for all
classes of cysteine-based PTPs. For comparable reasons, the P-loop structure
of Ci-VSP has been integrated in all panels (colored in orange). Class I PTPs
used for the alignment were the human isoforms of PTP1B (1nwe: green), of
the D1 domain of CD45 (1ygu, red), of PTEN (1d5r, blue), and of VHR (1vhr,
yellow). Class II PTPs are the bovine BHPTP (1dg9, yellow), and the human
isoforms HCPTPA (5pnt, blue) and HCPTPB (1xww, red). Class III PTPs are
the human isoforms Cdc25A (1c25, yellowish) and Cdc25B (1qb0, blue). In all
structures a phosphate anion is indicated in the active site. (C)The phosphate
group of the substrate is coordinated by hydrogen bonds with backbone
atoms of the P-loop residues, as demonstrated here for Ci-VSP. Residues
crucial in catalysis, Cys363 and Arg369, are particularly denoted.
the lack of the loop structures ﬂanking the active site. This will be
discussed later in this review.
Despite several similarities, class I to III PTPs show signiﬁcant
structural differences which will be discussed in the following.
THE CATALYTIC DOMAIN OF CLASS I PTPs
Catalytic domains of classical PTPs contain ∼240–280 amino
acids, and are the largest among the cysteine-based PTPs
(Figure 2A). The catalytic domains of dual-speciﬁc PTPs are
smaller; for example, the phosphatase of PTEN contains ∼180
amino acids. In particular, class I PTPs differ in the amount of
β-sheets in the protein core and of the α-helices ﬂanking the core.
These structural variations are one of the reasons for differences
in regulation of the catalytic activity and the cellular targeting of
class I PTPs (Tabernero et al., 2008).
Each class I PTP contains at least one catalytic domain. Exam-
ples for single phosphatase PTPs are PTP1B, VHR, laforin and
PTEN (Tonks, 2006; Pulido et al., 2013). Most of the receptor-like
PTPs contain two tandemly repeated catalytic domains, called D1
and D2 (Alonso et al., 2004), where the latter is located more dis-
tally to the membrane and has no catalytic activity (Streuli et al.,
1990). As shown for CD45, the D2 domain is proposed to play
a regulatory role for the phosphatase activity of D1 (Nam et al.,
2005).
Another characteristic feature that differs among class I PTPs is
the depth of the substrate binding pocket, with ∼9 Å for classical
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FIGURE 3 | Loop regions determine the conformation of the substrate
binding pocket in cysteine-based PTPs. (A) Sequence alignment of the
three loops which specify the conformation of the substrate binding pocket.
The P-loop contains the highly conserved CX5R motif that serves as active
site. The WPD-/DPYY- and the TI-/V-loops form the side walls of the
substrate binding pocket in class I and II PTPs. Because class III PTPs lack
the two latter loops, no sequence alignment could be performed for these
regions. Amino acids identiﬁed as identical to Ci-VSP are marked in gray.
Yellow colored residues are crucial for catalysis and widely conserved
among PTPs. UniProt accession numbers are indicated for all sequences
used for the alignment; in case of HCPTPA and HCPTPB, accession
numbers in the PDB database are given, since UniProt contains the same
reference sequence for both PTPs. (B,C) Structural alignment of the
phosphatase domain of Ci-VSP (colored in blue) with (B) the catalytic
domain of the human class I PTP, VHR (PDB accession number 1vhr) and
(C) the class II PTP, BHPTP (bovine heart PTP, PDB 1dg9). VHR and BHPTP
are colored in gray. Loops are highlighted in yellow for Ci-VSP and in
magenta for the respective PTP. The catalytic domain of Ci-VSP was
obtained by MD simulations (Hobiger et al., 2013) based on the crystal
structure of Matsuda et al. (2011; PDB 3awe).
and ∼6 Å for dual-speciﬁc PTPs (Barford et al., 1994; Stuckey
et al., 1994; Yuvaniyama et al., 1996). This difference is proposed
to determine the substrate speciﬁcity of the phosphatases (Barford
et al., 1994; Jia et al., 1995; Yuvaniyama et al., 1996). The deeper
pocket in classical PTPs permits the access to the active site only
for longer pTyr residues, whereas dual-speciﬁc phosphatases are
capable to bind pSer, pThr, and/or pTyr residues.
In case of the PIP-speciﬁc phosphatase PTEN, a crevice of 8 Å
in depth was observed in the crystal structure with a wider access
than in classical PTPs. This structural feature was suggested to be
the reason that PTEN preferentially accommodates the sterically
demanding PIP-substrates in its active site instead of pTyr, pSer,
or pThr substrates (Lee et al., 1999).
THE CATALYTIC DOMAIN OF CLASS II PTPs
LMW-PTPs contain one catalytic domain that consists of four
β-sheets ﬂanked by at least ﬁve α-helices on both sides (Figure 2A;
Su et al., 1994; Zhang et al., 1994a). In contrast to class I PTPs,
the P-loop is located at the N-terminal part of the phosphatase
connecting sheet β1 with helix α1. For example, the catalytically
active cysteine of the bovine liver LMW-PTP is located at position
12 in contrast to the soluble PTP1B, a class I PTP, which has the
cysteine at position 215 (Figure 3A). As mentioned above, the
P-loop in LMW-PTPs is surrounded by two loops: (i) the V-loop,
which differs in length and sequence among the phosphatases,
and (ii) the DPYY-loop. Both loops are as closely positioned
to the active site as the TI- and WPD-loops in class I PTPs
(Figures 3B,C). This conﬁguration leads to a compact substrate
binding pocket in LMW-PTPs, which is smaller, but similar to
that of class I PTPs. This is an interesting fact, since the overall
amino acid sequences of both PTP subclasses show no signiﬁ-
cant homology except for the P-loop motif (Figure 3A; Su et al.,
1994).
THE CATALYTIC DOMAIN OF CLASS III PTPs
The full length of Cdc25 phosphatases ranges from 300 to 600
amino acids (Kristjánsdóttir and Rudolph, 2004). Structurally,
the enzymes are divided into an N- and C-terminal region. The
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N-terminal part is highly variant among Cdc25 phosphatases and
contains several regulatory sites, which are involved in interac-
tions with other proteins (Conklin et al., 1995; Chen et al., 2000a;
Gnesutta et al., 2001; Kawabe et al., 2002), in phosphorylation or
ubiquitination (Hoffmann et al., 1993, 1994; Gabrielli et al., 1997;
Bernardi et al., 2000; Mailand et al., 2000; Donzelli et al., 2002).
TheC-terminal catalytic domain consists of about 200 residues.
It contains the active site motif CX5R, but lacks the serine or
threonine seven positions more C-terminal to the catalytically
active cysteine as found in other PTPs (Figure 3A). However,
the motif adopts the cradle-shaped conformation that is typical
for cysteine-based PTPs, with the cysteine and the arginine at
positions that allow for binding of the substrate in the active site
and for passing through the catalytic cycle (Figure 2B; Fauman
et al., 1998; Reynolds et al., 1999). Here, it should be noted that
in the crystal structure of Cdc25A (Fauman et al., 1998), the argi-
nine points away from the substrate binding pocket (Figure 2B);
this conﬁguration would be unfavorable for substrate binding.
However, in a structure subsequently described for the Cdc25A-
homolog Cdc25B, the arginine was positioned in a way that
resembles that of other PTPs (Reynolds et al., 1999). Additionally,
molecular dynamics (MDs) simulations carried out on Cdc25A
in presence of an oxyanion revealed a spontaneous ﬂip of the
P-loop segment during docking of the ligand into the substrate
binding pocket. In this way, the active site of Cdc25A adopts
a conformation similar to other PTPs (Kolmodin and Åqvist,
2000).
Apart from the active site motif, the α-helix following
C-terminally after the P-loop in Cdc25 matches well with the con-
ﬁguration found in class I and II PTPs (Figure 2B). However, the
catalytic domain of Cdc25 contains a smaller number of β-strands
and α-helices compared to class I PTPs (Figure 2A). Moreover,
the loop regions surrounding the substrate binding pocket in class
I and II PTPs are absent in Cdc25 phosphatases. Interestingly,
the overall structure of class III PTPs is less homologous to other
cysteine-based PTP subfamilies, but shows more similarities to
their ancestral relatives, the rhodanese enzymes (Fauman et al.,
1998; Reynolds et al., 1999).
GENERAL CATALYTIC MECHANISM OF PTPs
Since the three-dimensional structure of the active site is similar for
all three PTP subclasses, it is reasonable to assume that these phos-
phatases share a similar enzymatic reaction mechanism. Indeed,
results fromnumerous studies about different cysteine-basedPTPs
converge on the same general two-step catalytic mechanism that
applies for all class I to III phosphatases (Figure 4; Zhang et al.,
1994c; Denu and Dixon, 1995, 1998; Tonks and Neel, 2001;
Rudolph, 2002; Wang et al., 2003).
The reaction cycle starts with a nucleophilic attack on the
phosphorus atom of the substrate; a step that is mediated by
the cysteine in the PTP signature motif (Figure 4A). Here, a
general acid located in close vicinity to the catalytic cysteine
donates a proton to the substrate leaving group. In this way, a
cysteinyl-phosphate intermediate is formed and the dephospho-
rylated substrate dissociates from the active site cavity (Figure 4A;
Guan and Dixon, 1991; Jia et al., 1995; Denu et al., 1996;
Pannifer et al., 1998).
The second reaction step requires the presence of an activated
water molecule. This is achieved by a general base (Figure 4B).
The residue that serves as general acid during the ﬁrst reaction
step usually acts as general base in this second step by accept-
ing a proton from the activated water molecule (Taddei et al.,
1994; Denu et al., 1995a, 1996; Flint et al., 1997; Pannifer et al.,
1998). The resulting conﬁguration in the active site promotes the
hydrolysis of the cysteinyl-phosphate intermediate, whereby the
phosphate group is released. This step ﬁnalizes the reaction and
restores the conformation of the active site for a new catalytic cycle
(Figure 4C).
DIFFERENCES IN THE CATALYTIC CYCLE BETWEEN CLASS I, II, AND III
PTPs
A close look into the reaction scheme of cysteine-based PTPs
implies that not only the active site motif participates in catalysis,
but that all conserved loop regions are involved in the reaction.
In particular, for class I and II PTPs, the WPD- or DPYY-loop
contains the general acid for the ﬁrst reaction step (Figure 3A).
Due to the lack of this loop in class III PTPs, the existence
of a general acid has been controversial. An early study indi-
cated that an aspartate localized in the protein apart from the
P-loop serves as general acid in Cdc25 (Eckstein et al., 1996).
However, the crystal structure of the human isoform Cdc25A
had been resolved shortly afterwards, and it demonstrated a
structural rather than a catalytic role for this aspartate (Fau-
man et al., 1998). Based on this and the Cdc25B structure, one
of the two glutamates found in the X5-segment of the active site
motif (Figure 3A) were proposed to act as general acid (Fauman
et al., 1998; Reynolds et al., 1999). These results were further sup-
ported by MD simulations carried out on Cdc25B in presence
of its natural substrate (Arantes, 2008). In contrast to that, it
has been further suggested that Cdc25 phosphatases might not
require a general acid, because changes in pH in the active site
during the catalytic cycle could compensate for the lack of a pro-
ton donor (Rudolph, 2002, 2007). Controversially, several studies
imply that the general acid might be provided by the substrate
itself instead of being contributed by the phosphatase (Chen et al.,
2000b). However, up to now this question has not been completely
resolved.
For the second catalytic step in class I and II PTPs, the amino
acid that served as general acid in the previous reaction step is
now involved in the activation of a water molecule by acting as
general base. A different mechanism can be assumed for class III
PTPs again, because of the lack of the WPD- or a WPD-equivalent
loop. Studies addressing the inﬂuence of the pH on the active site
suggest that, also here, the two glutamates in the P-loop might be
involved in the activation of a critical water molecule (Rudolph,
2002, 2007). However, also this issue is still under controversial
discussion.
In the following, we want to elucidate in more detail the role of
the loop regions surrounding the active site. Because Cdc25 phos-
phatases are such a distinct subclass of cysteine-based PTPs with
large differences in the amino acids that might participate in the
catalytic reaction, we will exclude them from further discussion.
Readers interested in details of the catalytic mechanism of class III
PTPs are referred to the reviews of Rudolph (2002, 2007).
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FIGURE 4 | Catalytic cycle for cysteine-based PTPs. (A) In the resting
state, the sulfur of the catalytic cysteine is stabilized in an anionic thiolate
form. This is mediated by a hydrogen bond between the sulfur and the
hydroxyl oxygen of the conserved Thr-/Ser-side chain located in the P-loop.
Upon binding of the substrate, where the P-loop arginine is particularly
involved in the positioning of the substrate, the thiolate acts as catalytic
nucleophile by attacking the phosphorus atom of the substrate. The
formation of a cysteinyl-phosphate intermediate is facilitated by a general
acid (usually an aspartate from the WPD- or DPYY-loop ﬂanking the active
site), which donates a proton to the substrate leaving group. Subsequently,
the dephosphorylated substrate dissociates from the substrate binding
pocket. (B) The hydrolysis of the cysteinyl-phosphate intermediate is
mediated by an activated water molecule. Here, the aspartate or a
corresponding residue serves as general base by accepting one proton of
the water molecule. In several class I PTPs, the water molecule is
activated through hydrogen bonds with one or two polar amino acids in the
TI-loop, as it is indicated here for an interaction with a glutamine. After
accepting the proton from the general base, the phosphate dissociates
from the catalytic cysteine, so that (C) the resting state conformation of
the active site is reconﬁgured.
STRUCTURAL ELEMENTS DEFINING THE PHOSPHATASE
ACTIVITY OF PTPs
THE P-LOOP
As mentioned above, the active site motif CX5RS/T is highly con-
served among all cysteine-based PTPs (Figure 3A). This loop
region is located at the bottom of the substrate binding pocket and
is surrounded by other loop regions forming the side walls of the
pocket. Polar or charged residues in the P-loop are involved in sub-
strate docking and in the stabilization of the cysteinyl-phosphate
intermediate during the catalytic cycle. In the following, we will
discuss the functional relevance of critical amino acids in this loop
region.
The catalytic cysteine
The cysteine within the CX5RS/T-motif of the P-loop is the most
crucial residue for the catalytic reaction. The exchange of this
residue by serine results in the inactivation of all cysteine-based
PTPs. The cysteine-to-serine substitution in the active site is one
of the best characterized mutations of PTPs, since it is generally
used as negative control to analyze the catalytic activity of these
enzymes.
Apart from that, it has to be considered that the nucleophilic
attack mediated by the P-loop cysteine requires a correct posi-
tioning of the sulfhydryl-side chain with respect to the size of
the substrate binding pocket and the adjacent residues being
involved in the reaction steps. In this context, it has been fre-
quently described that the nucleophilic attack requires the sulfur
of the cysteine to be in an anionic thiolate conﬁguration (Zhang,
1993; Denu and Dixon, 1995; Evans et al., 1996; Lohse et al., 1997).
Crystal structures or results obtained by MD simulations showed
that this conﬁguration is enabled by a hydrogen bond between the
sulfur of the cysteine and the hydroxyl oxygen of the conserved
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P-loop threonine or serine seven positions C-terminally to the cys-
teine (Figures 2B, 3A, and 4A; Barford et al., 1994; Stuckey et al.,
1994; Yuvaniyama et al., 1996; Barford et al., 1998). As proposed by
Evans et al. (1996) for BHPTP (a class II PTP), the hydrogen bond
between the cysteine and the serine causes an unusually low pKa of
the sulfhydryl-side chain, with less than 4. Similarly, reduced pKa
values were also described for other cysteine-based phosphatases,
such as PTP1B (Lohse et al., 1997) or YopH from Yersinia pestis
(Zhang, 1993). This condition is proposed to stabilize the cys-
teine in the thiolate conﬁguration, so that the nucleophilic attack
on the substrate can proceed (Dillet et al., 2000). In addition to
that, Denu and Dixon (1995) proposed that the hydrogen bond
between the cysteine and the Thr/Ser might not only stabilize the
conformation of the enzyme’s resting state, but also that one of
the cysteinyl-phosphate intermediate. In this way, the hydrolysis of
the phosphate during the second reaction step might be facilitated
(Denu and Dixon, 1995).
Analogously in Ci-VSP, the catalytic cysteine and the P-loop
threonine are closely located to each other (Figure 2A); a conﬁgu-
ration that was found in crystal structures of the cytosolic domain
of Ci-VSP (Matsuda et al., 2011; Liu et al., 2012) and in a struc-
tural model of the protein obtained by MD simulations (Hobiger
et al., 2013). These results suggest the existence of a hydrogen bond
between the two residues also for Ci-VSP.However, it is still elusive
if this conﬁguration has any inﬂuence on the pKa value of the cys-
teine side chain. Therefore, the question remains if the sulfur is in
an anionic thiolate form inVSPs, andwhich role this conﬁguration
plays in catalysis.
Another interesting feature about the cysteine in the P-loop is
its sensitivity to redox modiﬁcation. Several studies demonstrated
that the presence of redox-reactive agents, such as H2O2 or NO,
reversibly eliminates the enzymatic activity of cysteine-based PTPs
(Denu and Tanner, 1998; Xu et al., 2002; Salmeen and Barford,
2005; Tonks, 2005; Ross et al., 2007; Conway et al., 2010; Ostman
et al., 2011; Miki and Funato, 2012). Formost PTPs, this inhibition
is caused by the formation of a disulﬁde bond between the P-loop
cysteine and another cysteine in its immediate environment, as
e.g., observed in PTEN (class I; Lee et al., 2002), HCPTP (class
II; Chiarugi et al., 2001), and Cdc25B (class III PTP; Buhrmann
et al., 2005). In case of PTP1B, the cysteine forms a sulphenyl-
amide bond under oxidizing conditions with the nitrogen atom
in the backbone of a serine that is located next to the catalytically
active side chain (Figure 5C; Salmeen et al., 2003; van Montfort
et al., 2003). When bound either in the sulphenyl-amide or in
the disulﬁde bond, the sulfhydryl group of the P-loop cysteine is
incapable of performing the nucleophilic attack on the phosphate
substrate, thus preventing catalysis.
For Ci-VSP, a disulﬁde bond has been found in one of the
crystal structures of the cytosolic domain (Figure 5B; Matsuda
et al., 2011). This bond was present between the catalytically active
residue Cys363 and the neighboring cysteine, Cys310. Accord-
ingly to other PTPs, Ci-VSP does not show phosphatase activity
toward PIP substrates in presence of H2O2 (Matsuda et al., 2011),
which demonstrates the inhibiting effect of oxidizing conditions
on catalysis.
The alignment of amino acid sequences shows that the cys-
teine corresponding to position 310 in Ci-VSP is highly conserved
FIGURE 5 | Redox modification of the catalytically active side chain in
cysteine-based PTPs. (A)The amino acid motif of Ci-VSP, which contains
Cys310 as putative interaction partner for the disulﬁde-bridge with the
catalytic Cys363, is aligned with sequences of VSP homologs from various
species (Dr, Danio rerio; Gg, Gallus gallus; Xl, Xenopus laevis; hu, human).
Additionally, PTEN isoforms from different species are included in this
alignment. Amino acid identities to Ci-VSP are colored in gray. Cys310 and
the corresponding position in the respective proteins are marked in yellow.
(B) For Ci-VSP, the disulﬁde bridge between Cys310 and the catalytic
Cys363 is shown as it has been identiﬁed in a crystal structure of the
cytosolic domain (PDB accession number 3awg; Matsuda et al., 2011).
(C) In crystal structures of the human PTP1B, the formation of a
sulphenyl-amide bond has been observed between the P-loop Ser216 and
the catalytically active Cys215 (PDB 1oes; van Montfort et al., 2003).
in VSPs and also in PTENs (Figure 5A). For the latter enzymes,
the redox regulation has been well-characterized (Lee et al., 2002;
Leslie et al., 2003; Cho et al., 2004; Yu et al., 2005; Kim et al., 2010;
Kitagishi and Matsuda, 2013). These facts indicate that the redox
regulation of VSPs might follow a similar pattern as described for
other PTPs.
The invariant arginine
Apart from the P-loop cysteine, the invariant arginine in the
active site motif has frequently been found to be critical for the
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correct binding of the substrate in the active site (Figure 2B;
Stuckey et al., 1994; Jia et al., 1995; Barford et al., 1998). Further-
more, this residue has been proposed to be responsible for the
stabilization of the cysteinyl-phosphate intermediate during the
reaction cycle (Zhang et al., 1994c; Pannifer et al., 1998). Based
on crystal structure analyses of the soluble phosphatase domain
of Ci-VSP, Liu et al. (2012) suggested that this arginine probably
marks the position of the phosphate at the substrate that has to be
cleaved.
Glycine versus alanine and the inﬂuence on substrate speciﬁcity
A further interesting residue in the P-loop motif is the amino
acid two positions more C-terminally from the catalytic cysteine.
While PTEN carries an alanine at this position, a glycine is found
there in VSPs (Figure 3A). PTEN speciﬁcally dephosphorylates
the 3′-phosphate from PI(3,4,5)P3 (Maehama and Dixon, 1998;
Maehama et al., 2001; Iwasaki et al., 2008), whereas Ci-VSP shows
a broader substrate spectrum by cleaving the 5′-phosphate from
PI(3,4,5)P3 and PI(4,5)P2 (Iwasaki et al., 2008; Halaszovich et al.,
2009) and – presumably with less efﬁciency – the 3′-phosphate
from PI(3,4)P2 (Sakata et al., 2011; Liu et al., 2012; Sakata and
Okamura, 2013). This difference raises the question whether the
substrate speciﬁcity of VSPs will be changed if the glycine in the
active site is substituted against alanine to mimic the substrate
binding pocket of PTEN.
In Ci-VSP, the mutation G365A signiﬁcantly decreases the
phosphatase activity toward PI(3,4,5)P3 and PI(4,5)P2 in vitro
and in vivo (Iwasaki et al., 2008; Liu et al., 2012). However, results
about an apparent 3′-phosphatase activity of the G365A mutant
are ambivalent. The puriﬁed catalytic domain of Ci-VSP which
lacks the transmembrane part of the protein shows increased activ-
ity toward PI(3,4)P2 and PI(3,5)P2 in vitro in comparison to the
wild type (Iwasaki et al., 2008). In contrast to that, the phosphatase
activity of the G365A full-length protein was signiﬁcantly reduced
in vivo toward PI(3,4)P2 compared to the wild type (Liu et al.,
2012). These results clearly demonstrate that data obtained by in
vitro and in vivo assays can diverge for VSPs. The reason for this
could be that the active site might adopt a different conformation
under in vitro conditions than in vivo, since the structural stabi-
lization of the substrate binding pocket through interactions with
the membrane surface or the voltage sensor domain cannot be
achieved in these experiments.
Interestingly, the G365A mutant was still capable to deplete
PI(4,5)P2 in vivo (Liu et al., 2012). Thus, the mutation in the
P-loop alone is not efﬁcient to convert Ci-VSP into an exclusive
3′-phosphatase like PTEN. Further studies are required to identify
the structural determinants for the substrate speciﬁcity in VSPs.
Speciﬁcity regarding protein- or lipid-derived substrates
Last but not least, the amino acid ﬁve residues C-terminally
from the active site cysteine (Figure 3A) also exhibits inter-
esting properties. In PTEN, the G129E mutation eliminates
PIP-speciﬁc phosphatase activity without affecting the activity
toward peptide-derived substrates (Furnari et al., 1997; Myers
et al., 1998; Ramaswamy et al., 1999). Gly129 is located at the bot-
tom of the substrate binding pocket. On the basis of the crystal
structure of PTEN, itwas proposed that theG129Emutationmight
result in the reduction of the wide access to the active site. In turn,
this might prevent the accommodation of PIP substrates, but does
not eliminate the capacity to bind phosphoprotein-substrates (Lee
et al., 1999).
In case of VSPs, no activity toward peptide-derived substrates
has been demonstrated so far. Because of the structural similarity
to PTEN, it would be interesting to see if VSPs are also capa-
ble to dephosphorylate this kind of substrates in addition to PIP
molecules.
THE WPD- OR DPYY-LOOP
The so-called WPD-loop of class I PTPs is located several amino
acid positions N-terminal to the P-loop (Figure 3). The name of
this region is derived from three amino acids in this motif, which
are conserved in several phosphatases, as for example in PTP1B,
YopH, and CD45 (Figure 3A). The nomenclature of this loop
persists for historical reasons, although some members of the PTP
family have been discovered that show considerable variations in
the WPD-loop sequence.
In case of class II PTPs, the motif which corresponds to the
WPD-loop is also highly conserved. Here, this region is termed
DPYY-loop, again because of its conserved sequence pattern
(Figure 3A; Tabernero et al., 1999).
The invariant aspartate
The most important residue in the WPD- or the DPYY-loop
is the invariant aspartate. Besides the cysteine and arginine
conserved in the P-loop, this residue is the third one within
the group of most crucial actors in the enzymatic reaction.
It mediates the formation of the cysteinyl-phosphate interme-
diate by acting as general acid during the ﬁrst step of the
catalytic cycle. In the second step, it acts as general base by
accepting the proton from an activated water molecule, which
enables the reconﬁguration of the active site for a new reac-
tion cycle (Figure 4; Taddei et al., 1994; Zhang et al., 1994b;
Denu et al., 1995a, 1996).
For class I PTPs, mutations of the invariant aspartate reduce or
abolish the phosphatase activity (Zhang et al., 1994c; Lohse et al.,
1997; Denu and Dixon, 1998). In case of rPTPα, a receptor-like
classical PTP, the substitution by glutamate preserves the charge at
this position, but changes the steric conditions in such a way that
the catalytic activity is decreased at least by two orders of mag-
nitude (Flint et al., 1997; Wu et al., 1997). However, substitution
of the aspartate in rPTPα by alanine completely eliminates the
catalytic activity toward pTyr (Wu et al., 1997).
Interestingly, it is known from studies on different PTPs that
an aspartate-to-alanine mutation in theWPD- or DYPP-loop gen-
erates highly efﬁcient substrate-trapping mutants (Garton et al.,
1996; Flint et al., 1997; Tonks and Neel, 2001; Blanchetot et al.,
2005; Monteleone et al., 2012). Garton et al. (1996) suggested
that the mutation enhances the hydrophobic properties of the
active site cleft and removes the repulsive electrostatic potential
between the aspartate and the phosphate moiety of the substrate.
In this way, the substrate-bound conformation could be stabilized
(Garton et al., 1996).
In agreement with these results, the corresponding D331A
mutation in Ci-VSP drastically slows down the off-motion of the
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voltage sensor domain after a voltage stimulation (Kohout et al.,
2010). This indicates a high energy barrier for the conformational
transition of the sensor domain into the resting state, which could
be due to the fact that theWPD mutation leads to a trapping of the
catalytic domain at its substrate at themembrane surface. Interest-
ingly, the D331A mutation shows a residual phosphatase activity
toward PI(3,4,5)P3 vesicles in vitro, but was completely inactive
toward PI(4,5)P2 in vivo (Kohout et al., 2010). These results imply
a drastic slow-down of the catalytic turnover rate, which might
arise from substrate trapping also in Ci-VSP.
Since the results obtained from Ci-VSP agree with those from
other PTPs, it can be assumed that the aspartate in the WPD-loop
of VSPs might play a similar role in catalysis as it does for class I
and II PTPs.
A glutamate instead of an aspartate with consequence for substrate
speciﬁcity
Quite recently, an “unusual” PTP has been identiﬁed that does
not ﬁt into this strict pattern of PTPs with the invariant aspartate
in the WPD-loop: the receptor-like class I phosphatase PTPRQ.
This enzyme contains a glutamate at the position corresponding
to the aspartate in other PTPs. Remarkably, receptor-like PTPs
had only been classiﬁed as classical PTPs so far. However, PTPRQ
has only little activity toward pTyr substrates, but displays speci-
ﬁcity for phosphoinositides (Oganesian et al., 2003; Seifert et al.,
2003; Park et al., 2013; Yu et al., 2013). Furthermore, in contrast
to PIP-speciﬁc PTPs like VSPs and PTENs, which show a sub-
strate preference for one position at the inositol ring, PTPRQ
dephosphorylates the 3′- and 5′- phosphates of the PIP head
group (Oganesian et al., 2003). Notably, if the glutamate in the
WPE-loop of PTPRQ is substituted by an aspartate mimicking the
sequence pattern of other PTPs, the phosphatase is converted into
a pTyr-speciﬁc phosphatase with no activity toward PIP substrates
(Oganesian et al., 2003).
THE TI-LOOP IN CLASS I PTPs VERSUS THE V-LOOP IN CLASS II PTPs
The third important loop in the catalytic domain of class I PTPs
is the TI-loop. Also here, the name results from a Thr-Ile pair
in this region that is conserved in many (including PTEN), but
not all PTPs (Figure 3A). Remarkably, the overall amino acid
sequence of the TI-loop is not as highly conserved as the one of
the P- and WPD-loop, which makes it difﬁcult to create a reliable
sequence alignment of this region. A structural alignment of dif-
ferent crystallized phosphatase domains on the basis of the P-loop
conformation ﬁnally enables the identiﬁcation of the region that
corresponds to the TI-loop (Figures 3B,C). The motives found by
this structural comparison are aligned in Figure 3A. This align-
ment illustrates the high sequence variation in this loop. However,
it further shows a notable similarity for class I PTPs: despite the
sequence variation, most of these PTPs contain at least one (i.e.,
PTEN) or even two glutamines (i.e., PTP1B, YopH, CD45) in the
TI-loop. Therefore, this region is often also referred to as Q-loop
for class I PTPs (Tabernero et al., 2008).
For class II PTPs, little homology of the V-loop to the corre-
sponding TI-loop of class I PTPs can be observed (Figure 3A). An
additional structural alignment of both regions revealed also no
signiﬁcant similarity, which makes the informational content of
the amino acid alignment in Figure 3A vague. However, as the TI-
loop in class I PTPs, the V-loop in class II PTPs contributes to one
of the side walls of the substrate binding pocket (Figure 3C). In
addition to that, class II PTPs differ in their capability to respond
to activators and inhibitors, which is caused by variations in the
amino acid sequence of the V-loop regions (Zhang et al., 1998;
Madhurantakam et al., 2005). Taken together, the V-loop plays an
important role for catalysis in class II PTPs, although it seems to be
completely different from the role of the TI-loop in class I PTPs.
Glutamine versus threonine versus glutamate in the TI-loop in class
I PTPs
There are many crystal structures of class I PTPs available that
contain a compound in the active site that mimics the bound
substrate. In these structures, the conserved glutamines of the TI-
loop stabilize awatermolecule, which is required for the hydrolysis
of the cysteinyl-phosphate intermediate during the second step
of the enzymatic reaction. For example, in structures of PTP1B
with a ligand bound to the active site, the two glutamines Gln262
and Gln266 coordinate the water molecule (Figure 6C; Brandao
FIGURE 6 | An activated water molecule is required for the second step
in catalysis of class I PTPs. (A)The substrate binding pocket is structurally
aligned for the human PTP1B (in light blue, PDB accession number 3ib0),
human PTEN (in yellow, PDB 1d5r), and Ci-VSP [in orange, modeled by MD
simulation based on the crystal structure of Matsuda et al. (2011) and
Hobiger et al. (2013) PDB 3awe]. The glutamines from theTI-loop of
hu-PTP1B and the corresponding amino acids in the other PTPs, the
invariant aspartate from theWPD-loop, and the catalytic cysteine from the
P-loop are represented as sticks. (B–D)The substrate binding pockets are
shown individually for the three PTPs with the following ligands bound to
the active site, as found in the respective crystal structures: L(+)-tartrate in
hu-PTEN, vanadate in hu-PTP1B, and sulfate in Ci-VSP. One water molecule
is coordinated adjacently to the aspartate and the ligand by theTI-loop
glutamines in hu-PTP1B (C) and by corresponding residues in Ci-VSP (D).
(B)This water molecule is absent in hu-PTEN. Thr167 that corresponds to
Gln262 in hu-PTP1B and Glu411 in Ci-VSP is oriented away from the active
site. One of the oxygen atoms of the bound tartrate forms a hydrogen bond
with the nitrogen of Gln171.
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et al., 2010). This conﬁguration has been further proposed to be
crucial in class I PTPs for positioning theWPD-loop in an optimal
conformation for catalysis (Pannifer et al., 1998; Brandao et al.,
2010).
With this knowledge at hand, the question remains: what role
does the TI-loop play in VSPs? In these phosphatases, two con-
served glutamines exist in the TI-loop, e.g., Gln408 and Gln415 in
Ci-VSP (Figure 3A). During the catalytic reaction, both residues
could putatively act as interaction partners for the coordination
of the water molecule. Therefore, we performed a structural
alignment of the phosphatase domains of Ci-VSP and PTP1B
(Figure 6). This comparison reveals that inCi-VSP,Glu411 instead
of Gln408overlapswithGln262 inPTP1B (Figure 6A). In this con-
ﬁguration, Gln415 of Ci-VSP is positioned in such a way that it
corresponds to Gln266 in PTP1B (Figures 6C,D). Furthermore,
the model of Ci-VSP, which was obtained by MD simulations
(Hobiger et al., 2013) predicts the coordinationof awatermolecule
by Glu411 and Gln415 in the immediate environment to the phos-
phate group of the substrate (Figure 6D). The invariant aspartate
in the WPD-loop of Ci-VSP, Asp331, additionally participates in
this conﬁguration; analogously to the aspartate in the WPD-loop
of PTP1B (Figures 6C,D).
It should be noted here, that no direct experimental evi-
dence exists so far, whether this conﬁguration is indeed adopted
during the catalytic cycle of Ci-VSP. Thus, our proposal just illus-
trates a hypothetical scenario based on modeling data. However,
studies on Glu411 mutants of Ci-VSP support our hypothesis.
Recently, Glu411 has been shown to be critical for catalysis in
Ci-VSP (Matsuda et al., 2011; Liu et al., 2012). Substitution of
Glu411 against hydrophobic residues (Ile, Leu, or Phe) reduced
the activity toward PI(3,4,5)P3 in vitro and almost abolished activ-
ity toward PI(4,5)P2 in vivo (Liu et al., 2012). Crystal structures of
the phosphatase domain of Ci-VSP suggested that Glu411 could
compete with the substrate for binding to the active site (Mat-
suda et al., 2011; Liu et al., 2012). Even more so, Liu et al. (2012)
proposed that Glu411 may act as molecular switch by changing
its position in such a way that the active site opens or closes;
a mechanism that was similarly described for Gln262 in PTP1B
(Brandao et al., 2010).
Interestingly, in the phosphatase domain of PTEN, which is
structurally highly homologous to that one of Ci-VSP, a threonine
is located at the position corresponding to Glu411 (Figure 3A).
Substitution of Glu411 against threonine in Ci-VSP causes a mod-
erate decrease in the phosphatase activity toward PI(3,4,5)P3 in
vitro and PI(4,5)P2 in vivo, and a strong reduction of its activity
toward PI(3,4)P2 in vivo (Liu et al., 2012). Taken together, these
ﬁndings suggest that a hydrophobic residue is less well-tolerated at
this position for the catalytic activity of Ci-VSP compared to the
polar side chain of threonine. This supports our hypothesis that
Glu411 might participate in coordinating the water molecule by
electrostatic interactions during the second step of catalysis.
But can the threonine in PTEN participate in the coordina-
tion of a water molecule? Such a conﬁguration can be studied
in the crystal structure of PTEN (Lee et al., 1999). A view into the
active site structure of PTENwith a bound tartratemolecule shows
that Thr167, which corresponds to Glu411 in Ci-VSP and Gln262
in PTP1B, is oriented away from the substrate binding pocket
(Figure 6B). Such a conﬁguration would contradict the assump-
tion that Thr167 is involved in the water molecule coordination.
However, it should be noted that the tartrate bound in the active
site inhibits the catalytic activity of PTEN (Lee et al., 1999). This
might be caused by the fact that upon binding of tartrate, Thr167
could be pushed into a position that prevents its participation
in catalysis and, consequently, eliminates phosphatase activity.
Therefore, it is possible that the crystal structure of PTEN does
not represent the catalytically active conformation of the active
site. Moreover, mutations T167A and Q171A in PTEN, which
would correspond to Q262A and Q266A in PTP1B, and E411A
and Q415A in Ci-VSP, reduced phosphatase activity in vitro by 60
to 75%, respectively (Lee et al., 1999). These results suggest a func-
tional relevance for both amino acids in the enzymatic reaction of
PTEN.
In conclusion, we suggest that the TI-loop in Ci-VSP is directly
involved in catalysis since it contains residues that might coordi-
nate the water molecule for the second step in the reaction cycle,
namely Glu411 and Gln415. Changing the electrostatic properties
by introducing a hydrophobic residue instead of Glu411 eliminates
or signiﬁcantly reduces catalytic activity, whereas the substitution
by a polar side chain such as threonine does not abolish enzymatic
function, but causes changes in substrate speciﬁcity. However, fur-
ther studies are required to elucidate exactly the interactions in the
active site of VSPs.
Other charged positions in the TI-loop of class I PTPs
Apart from Glu411 in Ci-VSP, at least one additional charged side
chain is located at the N-terminal part of the TI-loop in VSPs.
Again, a sequence comparison with other PTPs reveals large vari-
ations in this region (Figure 3A), which makes it difﬁcult to
speculate about the role of these charged residues for VSPs in
comparison to the results obtained for PTPs.
In case of Ci-VSP, recent studies suggested that Asp400 in
the N-terminal part of the TI-loop interacts with the region
that links the phosphatase to the adjacent voltage sensor domain
(Liu et al., 2012; Hobiger et al., 2013). Notably, the linker motif
of Ci-VSP is assumed to be critical for the coupling between
the catalytic and the voltage sensor domain (Murata et al., 2005;
Hossain et al., 2008; Villalba-Galea et al., 2009; Kohout et al., 2010;
Lacroix et al., 2011; Hobiger et al., 2012). In particular, the inter-
action between the linker and Asp400 was suggested to be crucial
for stabilizing the substrate binding pocket in a voltage-dependent
manner (Liu et al., 2012; Hobiger et al., 2013). This process might
be one critical step in transferring the conformational change
from the voltage sensor to the catalytic domain upon voltage
stimulation.
In PTEN, the region that is homologous to the linker of
VSPs has been proposed to act as phospholipid binding motif
(PBM), because it mediates the targeting of the enzyme to PIP-
containing membranes (Campbell et al., 2003; Das et al., 2003;
Iijima et al., 2004; Walker et al., 2004; Vazquez and Devreotes,
2006; Redfern et al., 2008). Analogously, this function has
also been suggested for the linker in Ci-VSP (Villalba-Galea
et al., 2009; Kohout et al., 2010; Hobiger et al., 2012). Dele-
tion of the PBM retains phosphatase activity of PTEN toward
water-soluble substrates, but eliminates the activity toward
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membrane-bound substrates (Iijima et al., 2004; Vazquez et al.,
2006). In contrast to that, the puriﬁed catalytic domain of
Ci-VSP does not show phosphatase activity in vitro if the
linker is deleted, neither toward membrane-bound substrates
nor the soluble PIP head group Ins(1,3,4,5)P4 (Kohout et al.,
2010).
Although the PBM in PTEN shares structural and functional
similarities with the linker in Ci-VSP, no direct interactions
between the PBM and regions in the catalytic domain have been
described for PTEN up to now. Upon membrane binding of the
PBM, conformational changes occur in the catalytic domain lead-
ing to the assumption of an allosteric activation mechanism in
PTEN (Campbell et al., 2003; McConnachie et al., 2003; Iijima
et al., 2004; Vazquez and Devreotes, 2006; Redfern et al., 2008).
However, the details of this process are still elusive and the ques-
tion remains, whether the interaction between the linker and
the TI-loop observed for Ci-VSP is an exclusive property of this
protein.
A MODEL FOR THE CATALYTIC MECHANISM IN VSPs
Including all results discussed above, we suggest the following two-
step catalytic reaction mechanism for Ci-VSP as representative for
all VSPs.
During the ﬁrst step in catalysis, the binding of the phospho-
rylated substrate is enabled by deﬁned structural properties of the
active site. Here, the phosphate group that will be cleaved from
the substrate is positioned by the P-loop Arg369, and a network of
hydrogen bonds formed by the backbone atoms of the active site
loop. The catalytic Cys363 is oriented in its position by a hydrogen
bond with the adjacent Thr370. This conﬁguration stabilizes the
sulfur of the cysteine in an anionic thiolate form. All these factors
ensure optimal reaction conditions, so that Cys363 acts as nucle-
ophile attacking the phosphate group of the substrate. With the
assistance of Asp331 from the WPD-loop, which donates a proton
to the substrate leaving group, a cysteinyl-phosphate intermediate
is formed, and the dephosphorylated substrate dissociates from
the active site pocket.
To return into the resting state, the phosphorus in the reac-
tion intermediate is attacked by an activated water molecule. The
activation of the water molecule is achieved by the coordination
through Glu411 and Gln415 from the TI-loop. Furthermore, one
of the protons of the water molecule is accepted by Asp331. In
this way, the phosphate group gets hydrolyzed, so that the initial
conformation of the active site is restored to start a new catalytic
cycle.
SUMMARY
Research on VSPs is still an emerging ﬁeld in membrane bio-
physics and cell biology. Since the activity of VSPs is switchable
by voltage stimulation, these enzymes have been mainly charac-
terized by electrophysiological methods. Taking their structural
identity and sequence pattern into account, VSPs can be classiﬁed
as members of the huge protein family of cysteine-based PTPs.
They dephosphorylate speciﬁcally PIP-lipids instead of phos-
photyrosine substrates. Therefore, and because of the structural
properties of their catalytic domain, VSPs belong to the subclass
of dual-speciﬁc class I PTPs.
The aim of this review is to point out that the information
presently available about VSPs and cysteine-based PTPs can be
well-integrated into a set of common principles. In particular,
we showed that all cysteine-based PTPs including VSPs share a
common folding pattern of their catalytic domain. In addition,
the two-step reaction mechanisms proposed for class I to III PTPs
can also be assumed forVSPs, since all results obtained so far from
this latter phosphatase family match well with the results about
well-characterized cysteine-based PTPs, such as PTP1B, CD45,
VHR, or VH1. However, many of the suggestions made here still
need experimental veriﬁcation. By linking the knowledge about
VSPs and PTPs, we want to inspire further research on VSPs to
contribute to and to beneﬁt from efforts in the ﬁeld of the large
phosphatase family to which they belong.
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